With the number of patients with both type 2 diabetes and established cardiovascular disease on the rise, a personalized patient approach to treating these two conditions is now more important than ever. Joining Dr. Jennifer Caudle to discuss the role of the cardiologist in managing patients with type 2 diabetes is Dr. Christie Ballantyne.

US18VZ00285 January 2019

Type 2 diabetes and established cardiovascular disease continues to impact patients and more focus is now set on addressing these patients’ unmet needs. Joining Dr. Jennifer Caudle is cardiologist Dr. Mikhail Kosiborod, who discusses a more reflexive approach to disease management that aims to close this gap in care.

US18VZ00284 January 2019

Since type 2 diabetes and cardiovascular disease often go hand in hand, having a care collaboration plan in place is essential in managing these conditions. Here to discuss both the challenges and opportunities that arise when collaborating patient care are cardiologists Dr. Mikhail Kosiborod and Dr. Christie Ballantyne.

US18VZ00286 January 2019

Newly developed and refined instruments are changing the setting of hysteroscopic procedures and giving way to improved patient satisfaction and practice efficiency. Dr. Soheil Hanjani evaluates the impact of incorporating hysteroscopy into the office and shares the compelling benefits you should know about.

To help physicians prepare for those times when they diagnose HIV-1 in treatment-naive patients, Dr. Leider shares his perspective on treating HIV-1 in patients that may have refused care at time of initial diagnosis, have not had resistance testing performed at time of diagnosis, or are unable to locate their medical records. Dr. Leider will also cover the background of the recent trial AMBER in HIV-1 treatment-naïve patients.

ARV - antiretroviral drugs

INDICATION

SYMTUZA® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults:

• who have no prior antiretroviral treatment history or
• who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

• Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of ...

Fostering an environment in which patients have access to necessary procedures that would normally require an OR has benefits for both you and your patients.

Global endometrial ablation, or GEA, has produced widespread and unsurpassed results for treating patients with abnormal uterine bleeding. It's time to explore new options for patients experiencing late-onset bleeding post-ablation and the possibilities of proper management.